|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gittes RF: Carcinoma of the prostate. N
Engl J Med. 324:236–245. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: TAX 327 Investigators: Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sulzmaier FJ and Ramos JW: RSK isoforms in
cancer cell invasion and metastasis. Cancer Res. 73:6099–6105.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu YN, Yin JJ, Abou-Kheir W, Hynes PG,
Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, et
al: miR-1 and miR-200 inhibit EMT via Slug-dependent and
tumorigenesis via Slug-independent mechanisms. Oncogene.
32:296–306. 2013. View Article : Google Scholar
|
|
7
|
Hotz B, Arndt M, Dullat S, Bhargava S,
Buhr HJ and Hotz HG: Epithelial to mesenchymal transition:
Expression of the regulators snail, slug, and twist in pancreatic
cancer. Clin Cancer Res. 13:4769–4776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ding G, Feng C, Jiang H, Ding Q, Zhang L,
Na R, Xu H and Liu J: Combination of rapamycin, CI-1040, and 17-AAG
inhibits metastatic capacity of prostate cancer via Slug
inhibition. PLoS One. 8:e774002013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C,
Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, et al: Up-regulation
of TWIST in prostate cancer and its implication as a therapeutic
target. Cancer Res. 65:5153–5162. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Whiteland H, Spencer-Harty S, Thomas DH,
Davies C, Morgan C, Kynaston H, Bose P, Fenn N, Lewis PD, Bodger O,
et al: Putative prognostic epithelial-to-mesenchymal transition
biomarkers for aggressive prostate cancer. Exp Mol Pathol.
95:220–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Umbas R, Isaacs WB, Bringuier PP,
Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM and Schalken
JA: Decreased E-cadherin expression is associated with poor
prognosis in patients with prostate cancer. Cancer Res.
54:3929–3933. 1994.PubMed/NCBI
|
|
12
|
Bertran E, Crosas-Molist E, Sancho P, Caja
L, Lopez-Luque J, Navarro E, Egea G, Lastra R, Serrano T, Ramos E,
et al: Overactivation of the TGF-β pathway confers a
mesenchymal-like phenotype and CXCR4-dependent migratory properties
to liver tumor cells. Hepatology. 58:2032–2044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Izumi K, Fang LY, Mizokami A, Namiki M, Li
L, Lin WJ and Chang C: Targeting the androgen receptor with siRNA
promotes prostate cancer metastasis through enhanced macrophage
recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med.
5:1383–1401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blum DL, Koyama T, M'Koma AE, Iturregui
JM, Martinez-Ferrer M, Uwamariya C, Smith JA Jr, Clark PE and
Bhowmick NA: Chemokine markers predict biochemical recurrence of
prostate cancer following prostatectomy. Clin Cancer Res.
14:7790–7797. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu X, Wang Y, Chen J, Ma H, Shao Z, Chen H
and Jin G: High expression of CX3CL1/CX3CR1 axis predicts a poor
prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg.
16:1493–1498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gaudin F, Nasreddine S, Donnadieu AC,
Emilie D, Combadière C, Prévot S, Machelon V and Balabanian K:
Identification of the chemokine CX3CL1 as a new regulator of
malignant cell proliferation in epithelial ovarian cancer. PLoS
One. 6:e215462011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jamieson WL, Shimizu S, D'Ambrosio JA,
Meucci O and Fatatis A: CX3CR1 is expressed by prostate epithelial
cells and androgens regulate the levels of CX3CL1/fractalkine in
the bone marrow: Potential role in prostate cancer bone tropism.
Cancer Res. 68:1715–1722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiao LJ, Chen YY, Lin P, Zou HF, Lin F,
Zhao LN, Li D, Guo L, Tang JB, Zheng XL, et al: Hypoxia increases
CX3CR1 expression via HIF-1 and NF-κB in androgen-independent
prostate cancer cells. Int J Oncol. 41:1827–1836. 2012.PubMed/NCBI
|
|
19
|
Yuan WC, Lee YR, Huang SF, Lin YM, Chen
TY, Chung HC, Tsai CH, Chen HY, Chiang CT, Lai CK, et al: A
cullin3-KLHL20 ubiquitin ligase-dependent pathway targets PML to
potentiate HIF-1 signaling and prostate cancer progression. Cancer
Cell. 20:214–228. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Philip B, Ito K, Moreno-Sánchez R and
Ralph SJ: HIF expression and the role of hypoxic microenvironments
within primary tumours as protective sites driving cancer stem cell
renewal and metastatic progression. Carcinogenesis. 34:1699–1707.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Traish AM and Morgentaler A: Epidermal
growth factor receptor expression escapes androgen regulation in
prostate cancer: A potential molecular switch for tumour growth. Br
J Cancer. 101:1949–1956. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Antonarakis ES, Carducci MA and
Eisenberger MA: Novel targeted therapeutics for metastatic
castration-resistant prostate cancer. Cancer Lett. 291:1–13. 2010.
View Article : Google Scholar
|
|
23
|
Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei
Y, Abbruzzese JL, Hortobagyi GN and Hung MC: Epidermal growth
factor receptor cooperates with signal transducer and activator of
transcription 3 to induce epithelial-mesenchymal transition in
cancer cells via up-regulation of TWIST gene expression. Cancer
Res. 67:9066–9076. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maretzky T, McIlwain DR, Issuree PD, Li X,
Malapeira J, Amin S, Lang PA, Mak TW and Blobel CP: iRhom2 controls
the substrate selectivity of stimulated ADAM17-dependent ectodomain
shedding. Proc Natl Acad Sci USA. 110:11433–11438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Floor S, van Staveren WC, Larsimont D,
Dumont JE and Maenhaut C: Cancer cells in epithelial-to-mesenchymal
transition and tumor-propagating-cancer stem cells: Distinct,
overlapping or same populations. Oncogene. 30:4609–4621. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tomaskovic-Crook E, Thompson EW and Thiery
JP: Epithelial to mesenchymal transition and breast cancer. Breast
Cancer Res. 11:2132009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shulby SA, Dolloff NG, Stearns ME, Meucci
O and Fatatis A: CX3CR1-fractalkine expression regulates cellular
mechanisms involved in adhesion, migration, and survival of human
prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
DeHaan AM, Wolters NM, Keller ET and
Ignatoski KM: EGFR ligand switch in late stage prostate cancer
contributes to changes in cell signaling and bone remodeling.
Prostate. 69:528–537. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shah RB, Ghosh D and Elder JT: Epidermal
growth factor receptor (ErbB1) expression in prostate cancer
progression: Correlation with androgen independence. Prostate.
66:1437–1444. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kenny PA: TACE: A new target in epidermal
growth factor receptor dependent tumors. Differentiation.
75:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gschwind A, Hart S, Fischer OM and Ullrich
A: TACE cleavage of proamphiregulin regulates GPCR-induced
proliferation and motility of cancer cells. EMBO J. 22:2411–2421.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Harris RC, Chung E and Coffey RJ: EGF
receptor ligands. Exp Cell Res. 284:2–13. 2003. View Article : Google Scholar : PubMed/NCBI
|
